EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Remodelin delays non‐small cell lung cancer progression by inhibiting NAT10 via the EMT pathway

Quanwei Guo iD, Weijun Yu, Jianfeng Tan, Jianhua Zhang, Jin Chen, Shuan Rao, Xia Guo, Kaican Cai iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Quanwei Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Epithelial-Mesenchymal Transition, Lung Neoplasms, N-Terminal Acetyltransferase E. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Innovative Talents Project of General Universities in Guangdong Province, Research Foundation of Shenzhen Hospital of Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer remains the foremost reason of cancer‐related mortality, with invasion and metastasis profoundly influencing patient prognosis. N‐acetyltransferase 10 (NAT10) catalyzes the exclusive N (4)‐acetylcytidine (ac4C) modification in eukaryotic RNA. NAT10 dysregulation is linked to various diseases, yet its role in non‐small cell lung cancer (NSCLC) invasion and metastasis remains unclear. Our study delves into the clinical significance and functional aspects of NAT10 in NSCLC.

Methods

We investigated NAT10's clinical relevance using The Cancer Genome Atlas (TCGA) and a group of 98 NSCLC patients. Employing WB, qRT‐PCR, and IHC analyses, we assessed NAT10 expression in NSCLC tissues, bronchial epithelial cells (BECs), NSCLC cell lines, and mouse xenografts. Further, knockdown and overexpression techniques (siRNA, shRNA, and plasmid) were employed to evaluate NAT10's effects. A series of assays were carried out, including CCK‐8, colony formation, wound healing, and transwell assays, to elucidate NAT10's role in proliferation, invasion, and metastasis. Additionally, we utilized lung cancer patient‐derived 3D organoids, mouse xenograft models, and Remodelin (NAT10 inhibitor) to corroborate these findings.

Results

Our investigations revealed high NAT10 expression in NSCLC tissues, cell lines and mouse xenograft models. High NAT10 level correlated with advanced T stage, lymph node metastasis and poor overall survive. NAT10 knockdown curtailed proliferation, invasion, and migration, whereas NAT10 overexpression yielded contrary effects. Furthermore, diminished NAT10 levels correlated with increased E‐cadherin level whereas decreased N‐cadherin and vimentin expressions, while heightened NAT10 expression displayed contrasting results. Notably, Remodelin efficiently attenuated NSCLC proliferation, invasion, and migration by inhibiting NAT10 through the epithelial‐mesenchymal transition (EMT) pathway.

Conclusions

Our data underscore NAT10 as a potential therapeutic target for NSCLC, presenting avenues for targeted intervention against lung cancer through NAT10 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungEpithelial-Mesenchymal TransitionLung NeoplasmsN-Terminal Acetyltransferase EAnimalsFemaleHumansMaleMiceMiddle AgedCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticMice, NudeN-Terminal AcetyltransferasesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

N‐acetyltransferase 10Remodelinepithelial‐to‐mesenchymal transitioninvasion and metastasislung cancermouse xenograftpatients‐derived organoidsproliferationtumorigenicity

Substanzen

N-Terminal Acetyltransferase EN-Terminal AcetyltransferasesNAT10 protein, human

Autor:innen und Institutionen

  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Department of Thoracic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
  • Bao'an District Hospital for Chronic Diseases Prevention and Cure, Shenzhen, China.
  • Science and Education Department, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
  • Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Center for Clinical Research and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, China.

ORCID-Profile: Quanwei Guo, Kaican Cai

Förderung

  • National Natural Science Foundation of China
  • Young Innovative Talents Project of General Universities in Guangdong Province
  • Research Foundation of Shenzhen Hospital of Southern Medical University

Zitieren

APA

Guo, Q., Yu, W., Tan, J., Zhang, J., Chen, J., Rao, S., Guo, X., & Cai, K. (2024). Remodelin delays non‐small cell lung cancer progression by inhibiting NAT10 via the EMT pathway. Cancer Medicine. https://doi.org/10.1002/cam4.7283

Vancouver

Guo Q, Yu W, Tan J, Zhang J, Chen J, Rao S, et al. Remodelin delays non‐small cell lung cancer progression by inhibiting NAT10 via the EMT pathway. Cancer Medicine. 2024. doi:10.1002/cam4.7283

BibTeX
@article{Guo2024,
  author = {Guo, Quanwei and Yu, Weijun and Tan, Jianfeng and Zhang, Jianhua and Chen, Jin and Rao, Shuan and Guo, Xia and Cai, Kaican},
  title = {Remodelin delays non‐small cell lung cancer progression by inhibiting NAT10 via the EMT pathway},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7283}
}
Kostenlos starten →